GE HealthCare has earned U.S. Food and Drug Administration (FDA) 510(k) clearance for True Definition DL, the latest addition to its portfolio of deep learning image reconstruction solutions for CT.

True Definition DL builds on the company’s TrueFidelity DL and True Enhance DL technologies to support quick scanning and broader coverage in pulmonary, musculoskeletal, and inner ear imaging. DL harnesses advanced neural networks and high-performance computing to enable sharper images, improved detectability, and faster processing compared to traditional approaches, according to GE HealthCare.

The technology delivers clarity in high-resolution CT imaging for bone and lung without compromising dose efficiency or acquisition speed. A DL-driven approach boosts spatial resolution across multiple directions, integrates artifact suppression, and supports high definition mode to improve visibility of small airways, pulmonary nodules, and trabecular bone patterns.

The company said the enhancement is crucial for high-contrast imaging tasks where diagnostic confidence relies on the ability to resolve subtle details. The solution also provides a 1024 matrix for high resolution display, with chest imaging achievable in under a second.

TrueFidelity DL can overcome traditional CT imaging tradeoffs, reducing noise while preserving natural image texture and sharpness during single and dial energy imaging. The high-definition images avoid the over-smoothed or artificial appearance of conventional methods to allow preferred image sharpness, low-contrast image quality, and preferred noise texture, at the same dose.

GE HealthCare also built True Enhance DL to offer improved contrast from standard single-energy CT scans to help visualize anatomy with more clarity. A dedicated deep neural network trained on GSI (Gemstone Spectral Imaging) monochromatic images to estimate 50 keV results (typically only achievable with dual-energy systems) brings the proven benefits of GSI into single-energy imaging.

“Image quality matters in healthcare—because when imaging performance is aligned with the specific diagnostic task, it plays a critical role in improving accuracy, enabling earlier detection, and guiding appropriate patient care,” said Chad Rowland, executive director, Global Premium CT and Photon Counting, GE HealthCare. “For clinicians, diagnostic confidence begins with the ability to clearly visualize subtle structures, differentiate tissues, and trust what is seen on the screen. For patients, that clarity can translate into quicker answers, fewer repeat scans and care plans tailored to their specific needs. With new tools like deep learning at our disposal, the industry has entered a new era in which reconstruction methods are more accessible to a broad range of providers, delivering sharp, consistent images and enabling care teams to make timely, well-informed decisions that directly impact patient outcomes.”